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Abstract
Background: A variety of techniques have been described which introduce scarless, site-specific
chromosomal mutations. These techniques can be applied to make point mutations or gene
deletions as well as insert heterologous DNA into bacterial vectors for vaccine development. Most
methods use a multi-step approach that requires cloning and/or designing repeat sequences to
facilitate homologous recombination. We have modified previously published techniques to
develop a simple, efficient PCR-based method for scarless insertion of DNA into Salmonella
enteritidis chromosome.
Results: The final product of this mutation strategy is the insertion of DNA encoding a foreign
epitope into the S. enteritidis genome without the addition of any unwanted sequence. This
experiment was performed by a two-step mutation process via PCR fragments, Red recombinase
and counter-selection with the I-SceI enzyme site. First, the I-SceI site and kanamycin resistance
gene were introduced into the genome of cells expressing Red recombinase enzymes. Next, this
sequence was replaced by a chosen insertion sequence. DNA fragments used for recombination
were linear PCR products which consisted of the foreign insertion sequence flanked by
homologous sequences of the target gene. Described herein is the insertion of a section of the M2e
epitope (LM2) of Influenza A virus, a domain of CD154 (CD154s) or a combination of both into
the outer membrane protein LamB of S. enteritidis.
Conclusion: We have successfully used this method to produce multiple mutants with no
antibiotic gene on the genome or extra sequence except those nucleotides required for expression
of epitope regions. This method is advantageous over other protocols in that it does not require
cloning or creating extra duplicate regions to facilitate homologous recombination, contains a
universal construct in which an epitope of choice can be placed to check for cell surface expression,
and shows high efficiency when screening for positive mutants. Other opportunities of this
mutational strategy include creating attenuated mutants and site-specific, chromosomal deletion
mutations. Furthermore, this method should be applicable in other gram-negative bacterial species
where Red recombinase enzymes can be functionally expressed.
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Scarless, site-directed mutagenesis on a bacterial chromo-
some is often a preferred method for studying a particular
region of DNA. This is due to the locational relevance and
stability of the construct. The approach of constructing
mutations on plasmids is still used consistently for many
applications but is not always appropriate in the case of
deletion mutations and vaccine therapy. In the case of live
bacterial vaccines, inserting heterologous antigens on sur-
face expressed proteins of bacteria has provided an effi-
cient means to display immunogenic antigens. However,
using plasmids for expression of these antigens comes
with the risk of posing a metabolic burden on the bacte-
rial cell, which causes decreased fitness or loss of the plas-
mid.
Still, several challenges exist for bacterial genomic muta-
genesis and include the following: designing and creating
delivery vectors that carry target genes with desired modi-
fications, overcoming the host restriction system, avoid-
ing the cause of a polar effect on downstream sequences,
and eliminating unwanted scar sequences or antibiotic
genes on the genome. All of these challenges have been
confronted and either completely or partially overcome
using a set of similar techniques. For example, a muta-
tional strategy using Red recombinase was introduced in
Escherichia coli as well as in Salmonella typhimurium which
resulted in site-directed, chromosomal insertions or dele-
tions but still had the problem of extraneous DNA left
behind on the genome [1,2]. Additionally, another
method was designed in which foreign epitopes were
added to the C-terminal end of genes in S. typhimurium,
yet, as before, an antibiotic gene or FRT scar sequence will
remain on the genome [3]. More desirable would be a
design scheme which would allow the epitope insertion at
any location within a gene but without any additional scar
sequence remaining. Therefore, improvements to this
method were made, using the Sce-I endonuclease as a
counter-selection tool, which could produce a scarless
mutation and eliminate extraneous DNA or antibiotic
resistance genes in the final mutational construct [4,5]. By
a stimulated, double-strand break of the DNA, markerless
mutations were constructed on BAC clones [5] as well as
on the E. coli genome [6]. Yet, these protocols using Sce-I
counter-selection require cloning and designing repeat
sequences flanking the DNA of interest. The repeat
sequences are the key elements of intramolecular recom-
bination, and, in some cases, the variability of chromo-
somal recombination requires extra screening by PCR to
determine which clones are positive mutants. Finally, a
transposon-based method has been established which
also uses Red recombinase and Sce-I counter-selection to
construct site-directed mutations but without the need for
cloning or designing repeat sequences [6]. This protocol
for transposon mutagenesis requires amplifying open
reading frames of genes from E. coli and performing in
vitro transposition using these PCR products. Because PCR
products ranged from 102–4617 bp in length, the trans-
poson could be flanked by approximately 50–2300 bp of
homology to the corresponding genomic site. The flank-
ing sequences provided by PCR products reduce the need
for designing sequences to facilitate recombination and
also has the potential for providing greater lengths of
homology. This might be more important for organisms,
other than E. coli, to overcome unique restriction systems.
For example, homologies ranging from 36–50 nucle-
otides are significant enough to allow recombination in E.
coli by Red recombinase [2], but it has been reported that
Salmonella enteritica serovar Enteritidis (S. enteritidis) may
require 100 bp – 1 kb of sequence homology for recombi-
nation to be efficient [7].
Presently, we have applied techniques from the afore
mentioned transposon-based method that allows scarless
mutations [6] with an overlapping extension PCR strategy
to chauffeur linear DNA fragments into a specific location
on a bacterial genome [8]. PCR products were designed to
carry insertion sequences flanked by 200–300 bp of
homology to the target site on the chromosome. The
resulting method uses the tailored-designed PCR products
to conduct a two-step, site-directed mutation inserting a
specific nucleotide sequence into the S. enteritidis genome
without leaving a scar. In the present study we inserted a
section of the M2e epitope (LM2) [9] from influenza A
virus, a domain of CD154 (CD154s) [10], also known as
CD40 ligand, or a combination of both into the outer
membrane protein lamB gene of S. enteritidis in order to
investigate the potential for a Salmonella-based vaccine
against avian influenza virus.
Results and discussion
Overview of mutational strategy
The goal of this study was to devise an efficient strategy to
make markerless, site-directed mutations on a bacterial
genome, using S. enteritidis as a model organism. The
experimental method made use of overlapping extension
PCR, the Red recombinase system, and an intermediary
insertion of the I-SceI endonuclease recognition site as a
counter-selection marker. The overall strategy is shown in
Figure 1. Overlapping extension PCR was used to produce
linear DNA with long flanking homology to the genome.
The Red recombinase system was used to mediate recom-
bination between incoming linear, PCR-generated DNA
with the bacterial genome. In the two-step mutation proc-
ess, the I-SceI site/kanamycin resistance (Kmr) cassette
was first inserted into the chromosome in the lamB gene
by homologous recombination. Then, this mutation was
replaced with the desired insertion sequence (LM2,
CD154s, combination sequence I or combination
sequence II). To make the replacement, a PCR product car-Page 2 of 10
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ously with a plasmid encoding the I-SceI endonuclease
enzyme used for counter-selection between the first and
second mutations.
I-SceI site/Kmr insertion mutation
The first mutation step involved designing a PCR frag-
ment, PCR-A, which would serve as the carrier of the I-SceI
site/Kmr cassette to be inserted into the lamB site. PCR-A
consisted of the I-SceI enzyme recognition site adjacent to
the Kmr gene with approximately 200–300 bp of flanking
DNA on each end homologous to the upstream and
downstream regions of lamB loop 9 insertion site (loop 9
up and loop 9 down, respectively). The fragment was
introduced into S. enteritidis cells expressing Red recombi-
nase enzymes. This step proved to be straightforward, and
selecting for Kmr colonies was the first criteria for identify-
ing potential positive clones. After screening a few colo-
nies by colony PCR, positive clones were sequenced for
the desired inserted I-SceI site/Kmr sequence, and the
identified mutants in S. enteritidis were designated SE164.
Genomic replacement of I-SceI/Kmr with LM2, CD154s, 
combination sequence I or combination sequence II
The second mutation step required constructing a PCR
fragment, referred to as PCR-B, consisting of the final
insertion sequence (LM2, CD154s, combination
sequence I or combination sequence II) flanked by lamB
homologous fragments. PCR-B amplicons have no selec-
tion marker and must be counter-selected after replace-
ment for the previous I-SceI site/Km r mutation in SE164.
Plasmid pBC-I-SceI encodes the chloramphenicol resist-
ance (Cmr) gene and the I-SceI enzyme, which will cut the
genome at the I-SceI site of SE164. Therefore, pBC-I-SceI
was electroporated into SE164 along with PCR-B. After
recombination of PCR-B to replace PCR-A, positive clones
were chosen based on the ability to grow on chloram-
phenicol (Cm) but not on kanamycin (Km). After DNA
Overall design scheme for making site-directed, mutations by inserting foreign DNA into S. enteritidis genome; Step 1: Overlap-ping exten o PCR is used to con truct PCR-A product consisting of the I-SceI recog ition sequence and Kmr gene flank d by homologous regions up t eam and downstream to he i ertion si e in loop 9 of lamB in almon lla nteritidisFigure 1
Overall design scheme for making site-directed, mutations by inserting foreign DNA into S. enteritidis genome; Step 1: Overlap-
ping extension PCR is used to construct PCR-A product consisting of the I-SceI recognition sequence and Kmr gene flanked by 
homologous regions upstream and downstream to the insertion site in loop 9 of lamB in Salmonella enteritidis. Step 2: PCR-A is 
introduced into the chromosome by electroporation and Red recombinase-mediated, homologous recombination. Step 3: The 
intermediate construct is isolated by selection on Km plates. Step 4: Overlapping extension PCR is used to construct PCR-B, 
with a foreign epitope sequence flanked by lamB regions as in PCR-A. Step 5: Co-electroporation of pBC-I-SceI and PCR-B. 
Here PCR-B is integrated into the genome by homologous recombination to replace the I-SceI recognition sequence and Kmr 
gene. Step 6: S. enteritidis containing the foreign epitope sequence is isolated by a counter-selection technique utilizing the pBC-
I-SceI plasmid which expresses the I-SceI enzyme and Cmr gene.
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tion of PCR-B into SE164, the strains were designated
SE172, SE173, SE180A, and SE189 for insert sequences
LM2, CD154s, (Gly)3-CD154s-(Gly)3-LM2-(Gly)3, and
(Ser)4-M2eA-(Ser)4-M2eA-(Ser)4-CD154-(Ser)4-LM2-
(Ser)4-LM2-(Ser)4, respectively. For electroporation of
LM2 and CD154s PCR-B products, at least 600 colonies
were Cmr. To test efficiency of counter-selection, fifty Cmr
colonies from each the LM2 and the CD154s electropora-
tion reaction were screened by restreaking on Km plates.
For both LM2 and CD154s clones, 96% of each proved to
be Cmr but Km sensitive (Kms). Ten random clones for
each the LM2 and CD154s insertion were used for PCR
with lam 3f and lam 3r then digested using unique restric-
tion enzymes sites for each insertion sequence. 100% of
clones tested by digestion were positive for the desired
mutation sequence, concluding the reliability and high
efficiency of this selection scheme. Sequencing results in
Figure 2 prove the replacement of the new sequence (LM2,
CD154s, combination sequence I or combination
Translated sequences of insertion and surrounding lamB region; Shown here are translated regions corresponding to nucle-otides 1243–1278 of the lamB ge e of Salmonella typhimu ium LT2 [16] and foreign inser ion sequen es placed in the homolo-gous regions of lamB in Sal onella e teritidisFigu  
Translated sequences of insertion and surrounding lamB region; Shown here are translated regions corresponding to nucle-
otides 1243–1278 of the lamB gene of Salmonella typhimurium LT2 [16] and foreign insertion sequences placed in the homolo-
gous regions of lamB in Salmonella enteritidis. Underlined nucleotides represent inserted sequences as named, and the predicted 
corresponding amino acids are highlighted. The arrow shows the site in wild type which corresponds to the insertion site of 
mutants.
wild type S.t.LT2
K  D  G  D  N  I  S  R  Y  A  A  A       
AAAGACGGCGATAACATTTCCCGTTATGCCGCAGCG
LM2 insertion in SE172 
K  D  G  D  N  E  V  E  T  P  I  R  N  I  S  R  Y  A  A           
AAAGACGGCGATAACGAAGTTGAAACCCCGATTCGTAACATTTCCCGTTATGCCGCA
CD154s insertion in SE173
 K  D  G  D  N  W  A  E  K  G  Y  Y  T  M  S  I  S  R  Y  A  A
AAAGACGGCGATAACTGGGCAGAAAAAGGTTATTATACCATGTCTATTTCCCGTTATGCCGCA
Combination sequence I insertion in SE180A
K  D  G  D  N  G  G  G  W  A  E  K  G  Y  Y  T  M  S  G  G  G     
AAAGACGGCGATAACGGTGGTGGTTGGGCAGAAAAAGGTTATTATACCATGTCTGGTGGTGGT
 E  V  E  T  P  I  R  N  G  G  G  I  S  R  Y  A  A
GAAGTTGAAACCCCGATTCGTAACGGTGGTGGTATTTCCCGTTATGCCGCA
Combination sequence II insertion in SE189 
 K  D  G  D  N  S  S  S  S  E  V  E  T  P  T  R  N  S  S  S  S
AAAGACGGCGATAACTCCTCCTCCTCCGAAGTTGAAACCCCGACCCGTAACTCCTCCTCCTCC
 E  V  E  T  P  T  R  N  S  S  S  S  W  A  E  K  G  Y  Y  T  M
GAAGTTGAAACCCCGACCCGTAACTCCTCCTCCTCCTGGGCAGAAAAAGGTTATTATACCATG
 S  S  S  S  S  E  V  E  T  P  I  R  N  S  S  S  S  E  V  E  T
TCTTCCTCCTCCTCCGAAGTTGAAACCCCGATTCGTAACTCCTCCTCCTCCGAAGTTGAAACC
 P  I  R  N  S  S  S  S  I  S  R  Y  A  A
CCGATTCGTAACTCCTCCTCCTCCATTTCCCGTTATGCCGCAPage 4 of 10
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addition of extraneous nucleotides.
LM2 antibody responses in chickens
After introducing attenuating mutations in the aroA gene
of SE172 and SE180A and in the aroA and htrA genes of
SE189, the resulting strains were designated SE171,
SE180B and SE197, respectively. LM2 antibody responses
were analyzed using serum from chickens challenged with
saline, S. enteritidis ΔaroA, SE171, SE180B or SE197. ELISA
results showed 3.00, 2.92 and 3.36 fold increases for
SE171, SE180B and SE197, respectively in production of
LM2 antibodies compared to S. enteritidis ΔaroA alone
(Figure 3). This clearly indicates the ability of the inserted
epitopes to be properly expressed.
Conclusion
Here, we have reported scarless, site-directed mutagenesis
performed in S. enteritidis. The described protocol proves
the ability of making exact mutations by inserting short
sequences ranging from 24–198 nucleotides, without any
excess sequence, into the lamB gene of S. enteritidis
genome. The basis for this method, which uses PCR prod-
ucts consisting of long homologous fragments flanking an
insertion sequence along with the functions of Red recom-
binase, helps dodge the S. enteritidis restriction system.
More significantly, we have provided a means to quickly
produce bacteria expressing heterologous epitopes on the
cell surface, which can then be tested for vaccine potential.
This scarless, site directed mutation strategy overcomes
the difficulties of chromosomal mutation and is simple in
the design and methods used. First, primers for overlap-
ping PCR must be designed. Then conventional tech-
niques using PCR, DNA purification and electroporation
can complete the project. Electroporation results as well as
screening for mutants on antibiotic media are effective
and convenient. One potential drawback of the experi-
mental design is that the final mutants will still carry the
pBC-I-SceI plasmid which has the Cmr gene. To make this
mutational strategy more significant for vaccine develop-
ment, constructing a temperature-sensitive plasmid
expressing I-SceI enzyme to replace pBC-I-SceI would
allow for a final bacterial vector free of antibiotic genes.
However, we found that pBC-I-SceI is not stable in the
cells upon infection of chickens. When we recover these
strains after vaccination of chickens, usually most of them
do not retain Cm resistance, indicating frequent loss of
the plasmid during infection. Such colonies isolated and
verified to have lost pBC-I-SceI could be considered
directly as vaccine candidates. On the other hand, an alter-
native method has been described which uses suicide
plasmids to introduce simultaneously the foreign insert
sequence plus the I-SceI site and I-SceI enzyme [5]. The
disadvantage is that these plasmids result in wild type and
mutant alleles causing decreased efficiency of positive
mutant selection. Also, extra cloning is required for plas-
mid construction, and a modular intermediate, allowing
for various epitope insertions, would not be available due
to the design scheme.
When creating insertion mutations, the length, nature and
location of the inserted sequence will be a factor of proper
expression and sustained fitness of the organism. A possi-
ble hindrance in expressing foreign DNA in bacterial cells
is the unknown ability of the organism to properly express
functional eukaryotic proteins or peptides in the same
fashion as the native organism. When applicable, our
strategy of inserting into the genome short, foreign
epitope sequences, which have been codon-optimized, as
a fusion protein may largely circumvent this potential
problem. Currently, we cannot confirm an upper limit on
the added nucleotide capacity of loop 9 but are continu-
ing to make more mutations with longer sequences. We
have already successfully inserted sequences of length 24,
30, 81 and 198 nucleotides in this loop 9 region, yet
experimental results seem to indicate that longer inserts
may have decreased the invasive ability of S. enteritidis
during chicken infection (data not shown). On the other
hand, chicken serum antibody responses testing the in vivo
expression of all ranges of insertion sequences have
shown significantly increased LM2-specific antibody titers
in chickens challenged with the epitope mutants com-
pared to those challenged with saline or S. enteritidis
ΔaroA alone (Figure 3). Experiments are underway to fur-
ther characterize the immunogenic potential of the vac-
cine strains developed in this study.
LM2 antibody responses in chickens; Results of chicken LM2 antibody respon es to oral gavag  challenge with saline, S.enteritidis ΔaroA (SE Δa oA), SE171, SE180B and SE197 are shownFigure 3
LM2 antibody responses in chickens; Results of chicken LM2 
antibody responses to oral gavage challenge with saline, 
S.enteritidis ΔaroA (SE ΔaroA), SE171, SE180B and SE197 are 
shown. If the challenge strain carries an inserted epitope in 
the loop 9 region of lamB, the length in number of mucle-
otides (nt) is indicated.
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BMC Biotechnology 2007, 7:59 http://www.biomedcentral.com/1472-6750/7/59Finally, this site-directed, scarless genomic mutagenesis
strategy has opened up many opportunities to manipulate
and examine the genome of S. enteritidis with acute specif-
icity. The possibilities for vaccine prospects include target-
ing other genes of interest with immunogenic flagging
potential as has been done with flagellin and secreted pro-
teins [11,12]. Also, live attenuated vaccines can be pro-
duced by conducting scarless deletions of virulence genes.
Previously, it was demonstrated that transposons, con-
taining the Kmr gene and the Sce-I site, could be inserted
into random chromosomal locations, including 1976
genes [6]. Therefore, the Sce-I site could serve well as a
counterselection marker, replacing altered alleles regard-
less of the location, directly supporting the feasibility of
this newly described mutagenesis protocol working in
other chromosomal contexts as well. Thus, this protocol
4a and 4b; Design scheme of PCR-A and PCR-B products used for introducing mutations; Figure 4a shows the design and process of amplification of PCR-A product which consists of the I-SceI ecognition site (I-SceI sit ), Kmr gene, an  200–300 bp of fla king homology to th loop 9 region of the lamB gene (loop 9 up an  loop 9 down)Figure
4a and 4b; Design scheme of PCR-A and PCR-B products used for introducing mutations; Figure 4a shows the design and 
process of amplification of PCR-A product which consists of the I-SceI recognition site (I-SceI site), Kmr gene, and 200–300 bp 
of flanking homology to the loop 9 region of the lamB gene (loop 9 up and loop 9 down). Figure 4b is representative of the 
PCR-B product of LM2 and CD154s only, which consists of either the LM2 or CD514s sequence flanked by the same loop 9 
regions as in PCR-A. Striped arrows indicate the section of the primer sequences that are complementary to loop 9 regions 
and thus are part of the homology overlap in PCR reactions. I-SceI site and epitope sequences which have been added to 
primer sequences are represented by arrows with the same pattern as the corresponding section in this DNA diagram. All 
primer sequences are italicized.
lam-dn-r
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epitope tags to proteins, adding or deleting promoters to
assess gene contribution and function or creating site-spe-
cific insertion or deletion mutations. Furthermore, this
method for conducting scarless, site-directed mutations
has potential in other gram-negative bacteria and would
be especially helpful for those organisms, other than E.
coli, which may also need long sequence homology for
efficient recombination.
Methods
Strains and Culture Conditions
All plasmids were first maintained in TOP10 E. coli cells
(Invitrogen, Carlsbad, CA, USA) unless described other-
wise. Salmonella enteritidis 13A [13] was used for introduc-
tion of mutations. Bacteria carrying plasmid pKD46 were
grown at 30°C, but growth of all other bacteria as well as
plasmid curing was done at 37°C.
Luria-Bertani (LB) mediawas used for routine growth of
cells, and SOC media (Invitrogen, Carlsbad, CA, USA)
Table 1: Primer sequences
Primer Amplified region Primer sequence
lam-up-f loop 9 up 5'TGTACAAGTGGACGCCAATC 3'
lam-up-r 5'GTTATCGCCGTCTTTGATATAGCC 3'
lam-dn-f loop 9 dn 5'ATTTCCCGTTATGCCGCAGC 3'
lam-dn-r 5'GTTAAACAGAGGGCGACGAG 3'
Km-f I-SceI/Kmr gene 5'GCTATATCAAAGACGGCGATAAC TAACTATAACGGTCCTAAGGTAGCGAATTTCCGGGGATCCGTCGA 3'
Km-r 5'GCTGCGGCATAACGGGAAAT TGTAGGCTGGAGCTGCTTCG 3'
Kan4f inside Kmr gene: sequencing 5'CAAAAGCGCTCTGAAGTTCC 3'
Kan4r 5'GCGTGAGGGGATCTTGAAGT 3'
lam-i1 M2e/loop 9 dn 5'GCTATATCAAAGACGGCGATAAC GAAGTTGAAACCCCGATTCGTAACATTTCC CGTTATGCCGCAGCG 3'
lam-i2 CD154s/loop 9 dn 5'GCTATATCAAAGACGGCGATAAC TGGGCAGAAAAAGGTTATTATACCATGTCTATTTCCCGTTATGCCGCAGC 3'
i2-i1h-f CD154s-(Gly)3-LM2-(Gly)3-loop 9 
dn
5'TGGGCAGAAAAAGGTTATTATACCATGTCTGGTGGTGGTGAAGTTGAAACCCCGATTCGTAACGGTGGTGGTA
TTTCCCGTTATGCCGCAGC 3'
i2-i1-r CD154s-(Gly)3-loop 9 Up 5'AGACATGGTATAATAACCTTTTTCTGCCCAACCACCACCGTTATCGCCGTCTT TGATATAGCC 3'
TJ1-f CD154-(Ser)4-LM2-(Ser)4-LM2-
(Ser)4-loop 9 dn
5'TGGGCAGAAAAAGGTTATTATACCATGTCTTCCTCCTCCTCCGAAGTTGAAACCCCGATTCGTAACTCCTCCT
CCTCCGAAGTTGAAACCCCGATTCGTAACTCCTCCTCCTCCATTTCCCGTTATGCCGCAGC 3'
TJ1-r CD154-(Ser)4-M2eA-(Ser)4-M2eA-
(Ser)4-loop 9 up
5'AGACATGGTATAATAACCTTTTTCTGCCCAGGAGGAGGAGGAGTTACGGGTCGGGGTTTCAACTTCGGAGGA
GGAGGAGTTACGGGTCGGGGTTTCAACTTCGGAGGAGGAGGAGTTATCGCCGTCTTTGATATAGCC 3'
lam 3f outer regions of loop 9: 
sequencing
5'GCCATCTCGCTTGGTGATAA 3'
lam 3r 5'CGCTGGTATTTTGCGGTACA 3'
aroA-1F aroA up 5'CTGGACGTCTCTCGCTATGG 3'
aroA-1R 5'TAGGAACTTCGAAGCAGCTCCAGCCTACACATAAAAACC CCACAGACTGG 3'
aroA-2F aroA dn 5'GGAATAGGAACTAAGGAGGATATTCATATGGTCTTCTGTTGCGCCAGT 3'
aroA-2R 5'CTTGCGAGAGTGCCCTAAAG 3'
htrA-1F htrA up 5'GGTTTTAGCCGCCTGCTT 3'
htrA-1R 5'TAGGAACTTCGAAGCAGCTCCAGCCTACACTTGCTGTGTACGTCAGATTCA 3'
htrA-2F htrA dn 5'GGAATAGGAACTAAGGAGGATATTCATATGTCACCTTTGTCCCCCTTC 3'
htrA-2R 5'GCATCATTTCGGCAGTCATA 3'
Kan 3F Kmr gene 5'GTGTAGGCTGGAGCTGCTTC 3'
Kan 3R 5'CATATGAATATCCTCCTTAG 3'
Italicized nucleotides are those which have complementation to either side of the lamB gene loop 9 insertion site, which corresponds to nucleotide 
1257 using S. typhimurium as an annotated reference genome. Bold font nucleotides represent the I-SceI site in the Km-f primer, and underlined 
sequences are all other insert sequences.Page 7 of 10
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When appropriate, the following antibiotics were added
to the media: ampicillin (Amp) at 100 μg/ml, kanamycin
(Km) at 50 μg/ml, and chloramphenicol (Cm) at 25 μg/
ml.
Plasmids
Plasmids pKD46, pKD13, and pBC-I-SceI used for the
present study were described previously [2,6]. Plasmid
pKD46 encodes Red recombinase enzymes which medi-
ate homologous recombination of incoming linear DNA
with chromosomal DNA. This plasmid also contains the
Amp resistance gene and is temperature-sensitive so that it
requires 30°C for maintenance in the cell. Plasmid
pKD13 served as a template for amplification of the Km
resistance (Kmr) gene used in overlapping PCR. Plasmid
pBC-I-SceI produces the I-SceI enzyme, which cleaves the
following 18 base pair, rare recognition sequence: 5'-TAG-
GGATAACAGGGTAAT-3' [14]. Also, the chloramphenicol
resistance (Cmr) gene is located on pBC-I-SceI, and this
plasmid can be maintained in the cell at 37°C.
PCR
All primers used for PCR are listed in Table 1. Typical PCR
conditions consisted of approximately 0.1 μg of purified
genomic, plasmid or PCR-generated DNA (Qiagen, Valen-
cia, CA, USA), 1× cloned Pfu polymerase buffer, 5 U Pfu
polymerase (Stratagene La Jolla, CA, USA), 1 mM dNTPs
(GE Healthcare Bio-Sciences Corp., Piscataway, NJ), 1.2
μM each primer in a total volume of 50 μL. The DNA
engine thermal cycler (Bio-Rad, Hercules, CA, USA) was
used with the following amplification conditions: 94°C
for 2 minutes; 30 cycles of 94°C sec for 30 sec, 58°C for
60 sec, 72°C for 90 sec per 1 kb; and 72°C for 10 minutes
for final extension. Each PCR product was gel purified
(Qiagen, Valencia, CA, USA) and either eluted in 25 μL EB
buffer for preparation of templates used in overlapping
extension PCR or in 50 μL EB buffer, ethanol precipitated
and suspended in 5 μL of ddH2O for electroporation into
S. enteritidis.
Electroporation
Transformation of pKD46 into S. enteritidis was the first
step carried out so that Red recombinase enzymes could
be used for mediating recombination of subsequent
mutations.
Plasmid pKD46 was harvested from E. coli BW25113 [2]
using a plasmid prep kit (Qiagen Valencia, CA, USA).
Then 0.5 μL of pKD46 DNA was used for transformation
into S. enteritidis 13A which had been prepared for electro-
poration according to a previously described protocol
with few modifications [2]. Briefly, cells were inoculated
into 10–15 mL of 2X YT broth and grown at 37°C over-
night. Then 100 μL of overnight culture was re-inoculated
into 10 mL fresh
2X YT broth at 37°C for 3–4 hours. Cells to be trans-
formed with pKD46 plasmid were heated at 50°C for 25
minutes to help inactivate host restriction [15]. Cells were
washed five times in ddH2O water and resuspended in 60μL of 10% glycerol. Cells were then pulsed at 2400–2450
kV for 1–6 ms, incubated in SOC for 2–3 hours at 30°C
and plated on LB media with appropriate antibiotics. S.
enteritidis transformants with pKD46 were maintained at
30°C. When these transformants were prepared for addi-
tional electroporation reactions, all steps were the same
except that 15% arabinose was added to induce Red
recombinase enzymes one hour prior to washing, and
cells did not undergo the 50°C heat step.
Loop 9 up- I-SceI/Kmr- Loop 9 down Construct
Introduction of I-SceI enzyme recognition site along with
the Kmr gene into loop 9 of the lamB gene was done using
the Red recombinase system and overlapping PCR as
described previously [2,8]. The insertion site corresponds
to nucleotide 1257 of the lamB gene using Salmonella typh-
imurium LT2 (S.typhimurium) as an annotated reference
genome [16]. First, the upstream and downstream regions
immediately flanking the loop 9 insertion site (loop 9 up
and loop 9 down, respectively) were amplified separately.
Primers used were lam-up-f and lam-up-r for loop 9 up
and lam-dn-f and lam-dn-r for loop 9 down. Then the Kmr
gene from pKD13 plasmid [2] was amplified using prim-
ers Km-f and Km-r. Here, the I-SceI enzyme site was syn-
thetically added to the 5' end of Km-f primer then
preceded by a region complimentary to the loop-up-r
primer. Likewise, a region complimentary to the loop-dn-
f primer was added to the 5' end of Km-r primer. The com-
plimentary regions allow all 3 PCR products to anneal
when used as templates in one PCR reaction. Figure 4a
represents this design scheme. PCR fragments consisting
of loop 9 up- I-SceI/Kmr- loop 9 down sequence (PCR-A)
were electroporated into S. enteritidis, which harbored
pKD46 and were induced by arabinose, and then plated
on LB with Km plates. To verify the correct sequence ori-
entation of the mutation, we performed colony PCR with
primer pairs Kan4F/lam3f and Kan4R/lam3r, where
Kan4F and Kan4R are Kmr gene-specific primers and
lam3f and lam3r are primers located outside the lamB
loop 9 region. These PCR fragments were gel purified
(Qiagen, Valencia, CA, USA) and used for DNA sequenc-
ing. The verified mutant which carried the I-SceI/Kmr frag-
ment in the mentioned loop 9 region of the lamB gene was
designated SE164.Page 8 of 10
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The final overlapping PCR fragment, PCR-B, contained the
added LM2, CD154s, combination sequence I or combina-
tion sequence II flanked by loop 9 up and down regions
(Figure 4b). Combination sequences consisted of LM2 or
an alternate M2e epitope associated with avian species
(M2eA) [17] and CD154s along with spacers such as Gly-
cine (Gly) or Serine (Ser) residues. Inserted sequences were
as follows: LM2: GAAGTTGAAACCCCGATTCGTAAC;
CD154s:
TGGGCAGAAAAAGGTTATTATACCATGTCT; combination
sequence I (Gly)3-CD154s-(Gly)3-LM2-(Gly)3:
GGTGGTGGTTGGGCAGAAAAAGGTTATTATACCAT-
GTCTGGTGGTGGTGAAGTTGAAACCCCGATTCG-
TAACGGTGGTGGT; and combination sequence II (Ser)4-
M2eA-(Ser)4-M2eA-(Ser)4-CD154-(Ser)4-LM2-(Ser)4-LM2-
(Ser)4:
TCCTCCTCCTCCGAAGTTGAAACCCCGACCCG-
TAACTCCTCCTCCTCCGAAGTTGAA ACCCCGACCCG-
TAACTCCTCCTCCTCCTGGGCAGAAAAAGGTTATTATA
CCATGTCT TCCTCCTCCTCCGAAGTTGAAACCCCGAT-
TCGTAACTCCTCCTCCTCCGAAGTTGAA ACCCCGAT-
TCGTAACTCCTCCTCCTCC.
To shorten the amount of steps for construction of this
next fragment, the LM2 or CD154s sequence was synthet-
ically added to the 5' end of the lam-dn-f primer and pre-
ceded by the complimentary region to the loop-up-r
primer. The previously used PCR product for loop 9 up
could be used together with the newly constructed PCR
product in which LM2 or CD154s were incorporated at
the 5' end of loop 9 down to perform the final PCR reac-
tion. However, for other insert sequences (referred to as
combination sequence I and II), an extra PCR step was
needed, due to the longer lengths of insert sequences, to
amplify loop 9 up with added nucleotides specific to
insertion sequences connected to loop-up-r primer. The
coding sequence for Gly (GGT) and Serine (TCC) as well
as all other amino acids were chosen based on compiled
data of the most frequently used codons in E. coli and Sal-
monella typhimurium proteins [18]. See Table 1 for further
details of primer design.
Genomic replacement of I-SceI/Kmr with LM2, CD154s, 
combination sequence I or combination sequence II
PCR-B products and plasmid pBC-I-SceI (at a molar ratio
of approximately 40:1) [6] were simultaneously electro-
porated into SE164 cells, which carried the I-SceI/Kmr
fragment in loop 9 of the lamB gene. Clones for each PCR-
B recombination mutation were chosen according to the
ability to grow on Cm plates but not on Km plates, due to
the replacement of PCR-B for the Kmr encoding PCR-A
sequence. Modified regions in the selected clones were
PCR-amplified, and DNA sequences were determined
using primers lam3f and lam3r located outside the loop 9
down and up amplified regions. The assigned strain num-
bers for epitope insertions LM2, CD154, combination
sequence I and combination sequence II were SE172,
SE173, SE180A and SE189, respectively.
Creating attenuating mutations in aroA and htrA genes
Bacteria carrying the mentioned epitope sequences were
attenuated so that vaccine potential and epitope expres-
sion could be assessed. Attenuation was done by inserting
the Kmr gene in place of and thereby deleting aroA and/or
htrA. This was done by first using overlapping PCR with
primers aroA-1F, aroA-1R, aroA-2F and aroA-2R for the
aroA deletions and htrA-1F, htrA-1R, htrA-2F and htrA-2R
for the htrA deletions. The Kmr gene was amplified from
pKD4 using primers Kan 3F and Kan 3R (Table 1). Addi-
tionally, the previously described pCP20 was introduced
into ΔaroA cells to remove the Kmr gene from the aroA
gene only when the htrA gene was also to be deleted [2].
Mutations were made in the aroA gene of SE172, SE173,
SE180A, and in the aroA and htrA genes of SE189 with the
resulting strain numbers being SE171, SE174, SE180B and
SE197, respectively.
Challenge of S. enteritidis mutants in chickens
At day of hatch, broiler chicks were challenged via oral
gavage with saline or 107 CFU of S. enteritidis ΔaroA,
SE171, SE180B or SE197. Blood samples were taken at
day 20 post-hatch to test for LM2 specific IgG antibody tit-
ers.
Measuring LM2 antibody titers
LM2 antibody responses in challenged chickens were cal-
culated using an antigen capture ELISA. Briefly, LM2 con-
jugated to BSA was added to a 96 well microtiter plate and
allowed to incubate overnight at 4°C. Plates were then
rinsed and incubated with chicken serum for 2 hours.
Then, plates were rinsed and a detection antibody was
added and incubated for an additional 1 hour. Afterwards,
plates were again rinsed, and a peroxidase substrate kit
was used to obtain absorbance readings at 450 nm with a
spectrophotometer. Positive and negative controls were
included which consisted of the LM2 polyclonal antibody
mentioned above and serum from an untreated bird,
respectively. All samples were measured, and sample to
positive control ratios (S/P ratios) were calculated using
the following equation: (sample- negative control)/(posi-
tive control – negative control).Page 9 of 10
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